Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer

References

• SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience19872351771823798106
   PubMed Web of Science ®Google Scholar
• SlamonDJGodolphinWJonesLAStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience19892447077122470152
   PubMed Web of Science ®Google Scholar
• MartyMCognettiFMaraninchiDRandomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupJ Clin Oncol2005234265427415911866
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med200134478379211248153
   PubMed Web of Science ®Google Scholar
• GianniLPienkowskiTImYHEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol201213253222153890
   PubMed Web of Science ®Google Scholar
• PerezEARomondEHSumanVJFour-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31J Clin Oncol2011293366337321768458
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med20053531659167216236737
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med20053531673168416236738
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med20113651273128321991949
   PubMed Web of Science ®Google Scholar
• LiberatoNLMarchettiMBarosiGCost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol20072562563317308267
   PubMed Web of Science ®Google Scholar
• MisbahSSturzeneggerMHBorteMSubcutaneous immunoglobulin: opportunities and outlookClin Exp Immunol2009158 Suppl 1515919883424
   PubMed Web of Science ®Google Scholar
• GardulfABorteMOchsHDNicholayUVivaglobin Clinical Study GroupPrognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapyClin Immunol2008126818817964220
   PubMed Web of Science ®Google Scholar
• HoffmannFGrimbacherBThielJHome-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiencyEur J Med Res20101523824520696632
   PubMed Web of Science ®Google Scholar
• ThamerMZhangYKaufmanJStefanikKCotterDJFactors influencing route of administration for epoetin treatment among hemodialysis patients in the United StatesAm J Kidney Dis200648778716797389
   PubMed Web of Science ®Google Scholar
• LaurentTCFraserJRHyaluronanFASEB J19926239724041563592
   PubMed Web of Science ®Google Scholar
• MenzelEJFarrCHyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic usesCancer Lett19981313119839614
   PubMed Web of Science ®Google Scholar
• DunnALHeavnerJERaczGHyaluronidase: a review of approved formulations, indications and off-label use in chronic pain managementExpert Opin Biol Ther20101012713120420518
   PubMed Web of Science ®Google Scholar
• FrostGIRecombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administrationExpert Opin Drug Deliv2007442744017683255
   PubMed Web of Science ®Google Scholar
• AdamsLAdjuvants to local anaesthesia in ophthalmic surgeryBr J Ophthalmol2011951345134921441237
   PubMed Web of Science ®Google Scholar
• ForbesGBDeisherRWEffect of hyaluronidase on the subcutaneous absorption of electrolytes in humansScience195011117717915403119
   PubMed Web of Science ®Google Scholar
• EberhartAHWeilerCRErieJCAngioedema related to the use of hyaluronidase in cataract surgeryAm J Ophthalmol200413814214315234297
   PubMed Web of Science ®Google Scholar
• EboDGGoossensSOpsomerFFlow-assisted diagnosis of anaphylaxis to hyaluronidaseAllergy2005601333133416135006
   PubMed Web of Science ®Google Scholar
• BookbinderLHHoferAHallerMFA recombinant human enzyme for enhanced interstitial transport of therapeuticsJ Control Release200611423024116876899
   PubMed Web of Science ®Google Scholar
• CsokaABFrostGISternRThe six hyaluronidase-like genes in the human and mouse genomesMatrix Biol20012049950811731267
   PubMed Web of Science ®Google Scholar
• WolfRAChaungLYO’HaraDThe serum kinetics of bovine testicular hyaluronidase in dogs, rats and humansJ Pharmacol Exp Ther19822223313377097553
   PubMed Web of Science ®Google Scholar
• YocumRCKennardDHeinerLSAssessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trialJ Infus Nurs20073029329917895809
   PubMedGoogle Scholar
• ThomasJRYocumRCHallerMFFlamentJThe INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteersJ Pain Symptom Manage20093867368219819667
   PubMed Web of Science ®Google Scholar
• ThomasJRWallaceMSYocumRCThe INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illnessJ Pain Symptom Manage20093866367219819665
   PubMed Web of Science ®Google Scholar
• AllenCHEtzwilerLSMillerMKRecombinant human hyaluronidase-enabled subcutaneous pediatric rehydrationPediatrics2009124e858e86719805455
   PubMed Web of Science ®Google Scholar
• MuchmoreDBVaughnDEReview of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulationsJ Diabetes Sci Technol2010441942820307403
   PubMedGoogle Scholar
• HarbGLebelFBattikhaJThackaraJWSafety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteersCurr Med Res Opin20102627928819947907
   PubMed Web of Science ®Google Scholar
• ChoHSMasonKRamyarKXStructure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature200342175676012610629
   PubMed Web of Science ®Google Scholar
• SliwkowskiMXLofgrenJALewisGDHotalingTEFendlyBMFoxJANonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)Semin Oncol199926607010482195
   PubMed Web of Science ®Google Scholar
• ClynesRATowersTLPrestaLGInhibitory Fc receptors modulate in vivo cytotoxicity against tumor targetsNat Med2000644344610742152
   PubMed Web of Science ®Google Scholar
• MolinaMACodony-ServatJAlbanellJRojoFArribasJBaselgaJTrastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cellsCancer Res2001614744474911406546
   PubMed Web of Science ®Google Scholar
• WynneCHarveyVSchwabeCWaakaDMcIntyreCBittnerBComparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancerJ Clin PharmacolFebruary 22, 2012 [Epub ahead of print.]
   Google Scholar
• IsmaelGHeggRMuehlbauerSSubcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trialLancet Oncol20121386987822884505
   PubMed Web of Science ®Google Scholar